Vaxgen (Anthrax Vaccine Assets and Technology) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Vaxgen (Anthrax Vaccine Assets and Technology) General Information

Description

Anthrax vaccine program and related assets and technology. The portfolio includes all assets and rights related to a recombinant protective antigen (rPA) anthrax vaccine product.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Biotechnology
Corporate Office
  • 349 Oyster Point Boulevard
  • Suite 10
  • South San Francisco, CA 94080
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vaxgen (Anthrax Vaccine Assets and Technology) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Vaxgen (Anthrax Vaccine Assets and Technology)‘s full profile, request access.

Request a free trial

Vaxgen (Anthrax Vaccine Assets and Technology) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Vaxgen (Anthrax Vaccine Assets and Technology)‘s full profile, request access.

Request a free trial

Vaxgen (Anthrax Vaccine Assets and Technology) FAQs

  • Where is Vaxgen (Anthrax Vaccine Assets and Technology) headquartered?

    Vaxgen (Anthrax Vaccine Assets and Technology) is headquartered in South San Francisco, CA.

  • What industry is Vaxgen (Anthrax Vaccine Assets and Technology) in?

    Vaxgen (Anthrax Vaccine Assets and Technology)’s primary industry is Buildings and Property.

  • Is Vaxgen (Anthrax Vaccine Assets and Technology) a private or public company?

    Vaxgen (Anthrax Vaccine Assets and Technology) is a Private company.

  • What is the current valuation of Vaxgen (Anthrax Vaccine Assets and Technology)?

    The current valuation of Vaxgen (Anthrax Vaccine Assets and Technology) is 0000.

  • What is Vaxgen (Anthrax Vaccine Assets and Technology)’s current revenue?

    The current revenue for Vaxgen (Anthrax Vaccine Assets and Technology) is 000000.

  • Who are Vaxgen (Anthrax Vaccine Assets and Technology)’s investors?

    Vaxgen has invested in Vaxgen (Anthrax Vaccine Assets and Technology).

  • When was Vaxgen (Anthrax Vaccine Assets and Technology) acquired?

    Vaxgen (Anthrax Vaccine Assets and Technology) was acquired on 05-May-2008.

  • Who acquired Vaxgen (Anthrax Vaccine Assets and Technology)?

    Vaxgen (Anthrax Vaccine Assets and Technology) was acquired by Emergent BioSolutions.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »